Ondansetron/Pramipexole - Alto Neuroscience
Alternative Names: ALTO-207; CTC-501; Pramipexole/Ondansetron - Alto NeuroscienceLatest Information Update: 13 Apr 2026
At a glance
- Originator Chase Therapeutics
- Class Antidepressants; Benzothiazoles; Carbazoles; Imidazoles; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Serotonin 5 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Major depressive disorder
Most Recent Events
- 01 Apr 2026 Alto Neuroscience plans a phase IIb trial for Treatment resistant depressive disorder (Adjunctive treatment, Treatment experienced) (PO) in first half of 2026
- 16 Mar 2026 Bayer announces intention to submit NDA for Treatment resistant depressive disorder
- 14 Jan 2026 US PTO issued a patent covering methods of treating depression with ondansetron/pramipexole